Metagenomi, Inc. is a precision genetic medicine company. The Company is focused on developing curative therapeutics for patients using its comprehensive metagenomics derived toolbox. Its diverse and modular genome editing toolbox is designed to precisely target any site in the human genome. Its comprehensive genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, including prime editing systems and clustered regularly interspaced short palindromic repeat (CRISPR)-associated transposases (CASTs). It has also developed a modular toolbox of genome editing systems that will allow it to interact with the human genome in a site-specific manner, where each tool can be matched to specific disease targets. The Company uses artificial intelligence and its metagenomics platform to develop curative genetic medicines.
์ข
๋ชฉ ์ฝ๋ MGX
ํ์ฌ ์ด๋ฆMetagenomi Inc
์์ฅ์ผFeb 09, 2024
CEOIrish (Jian)
์ง์ ์202
์ ํOrdinary Share
ํ๊ณ ์ฐ๋ ์ข
๋ฃFeb 09
์ฃผ์5959 Horton St
๋์EMERYVILLE
์ฆ๊ถ ๊ฑฐ๋์NASDAQ OMX - NASDAQ BASIC
๊ตญ๊ฐUnited States of America
์ฐํธ ๋ฒํธ94608
์ ํ15108714880
์น์ฌ์ดํธhttps://metagenomi.co/
์ข
๋ชฉ ์ฝ๋ MGX
์์ฅ์ผFeb 09, 2024
CEOIrish (Jian)
์ง๋ 5๋
๋์ ์ด
0.00
USD์ ๋ฐฐ๋น๊ธ์ด ๋ถ๋ฐฐ๋์์ต๋๋ค.

๋ฐ์ดํฐ ์์